- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01845285
A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System (DISCOVER)
A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System for the Treatment of Patients With Severe Aortic Stenosis
The purpose of this postmarket Registry is to assess the standard of care and clinical outcomes of the Direct Flow Medical Transcatheter Aortic Valve System used in clinical routine according to the approved commercial indications. Procedures and assessments required by this registry are generally considered standard of care for Transcatheter Aortic Valve Replacement patients.
Evaluation criteria will be the incidence of mortality/morbidity and adverse events clinical performance, and hemodynamic performance of the DEVICE via ultrasound (echo) and angiographic imaging.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The patient population will include patients who are candidates for transcatheter aortic valve replacement (TAVR). According to routine practice, the heart team (interventional cardiologist and cardiothoracic surgeon) makes a choice to use the Direct Flow Medical Aortic Valve System, compared to other available TAVR prostheses, on the basis of clinical and surgical considerations. Therefore, the valve is implanted when the heart team decides that this product is best suited to the specific patient.
In order to be enrolled in this Registry, the patient must be a candidate for the implantation of the Direct Flow Medical Transcatheter Aortic Valve System, based on the commercial indications as stated in the Instructions for Use.
Therefore, candidates for this study must meet the following criteria (Indications for Use):
- Age > 70 years old
Severe aortic valve stenosis determined by echocardiogram and Doppler:
- mean gradient >40 mmHg or peak jet velocity >4.0 m/s AND
- aortic valve area ≤0.8 cm2 or aortic valve area index ≤0.5 cm2/m2
- Symptomatic aortic valve stenosis (angina, congestive heart failure, NYHA Functional Class ≥ II, or syncope).
- Patient is an extreme risk candidate for open surgical aortic valve repair such that the site Investigators (interventional cardiologist and cardiothoracic surgeon) agree that medical factors preclude operation, based on the conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement due to the patient's co-morbidities (such as, but not limited to, severe COPD, porcelain aorta, previous thorax irradiation) or logistic EuroSCORE ≥ 20.
All the Registry clinical evaluations and tests performed are generally considered standard of care for TAVR patients. When these recommendations conflict with the standard of care at the Registry site, the standard of care should prevail. In addition to the standard of care, the Sponsor recommends one brief additional evaluation (the EQ-5D quality of life measure) be conducted. Failure to perform this evaluation shall not be considered a protocol deviation.
Baseline Clinical Evaluation
- Medical History and Physical Exam
- 12 lead ECG and Arrhythmia Assessment
- Logistic EuroSCORE/STS Score
- New York Heart Association (NYHA) functional status
- Modified Rankin Score Assessment (mRS)
- Current Cardiac Medications Baseline Imaging Studies
- Transthoracic Echo (TTE)
- CT Scan (ECG triggered, contrast enhanced)
Aorto-Iliac Angiogram:
- Peripheral Evaluation
- Coronary Evaluation
All patients will have clinical follow-up at hospital discharge, 30 days, 12 months and annually to 3 years and undergo the following evaluations:
- Physical Exam
- 12 lead ECG and Arrhythmia Assessment
- New York Heart Association (NYHA) functional status
- Modified Rankin Score Assessment (mRS) if symptomatic for stroke
- Current Cardiac Medications
- Transthoracic echo (TTE) Patients in whom the heart team has planned to use the Direct Flow Medical Transcatheter Aortic Valve System valve, are informed of the DISCOVER Registry and their consent to participate is required. This study intends to monitor the clinical condition of the patient for a period of 3 years after the operation. By agreeing to participate, the patient agrees to undergo clinical assessments and specific tests at certain intervals (prior to the procedure; during the implantation; at hospital discharge, at 30 days after the procedure, and at 1 year, 2 and 3 years later); the patient also agrees to the collection of these daThe purpose of this Registry is to monitor outcomes data for the Direct Flow Medical Transcatheter Aortic Valve System in the Post Market phase. The primary outcome of interest is freedom from all-cause mortality at 30 days. The results from the pivotal CE mark study (IP 010) yielded a 30 day freedom from all-cause mortality rate of 97%. Should the "true" rate be 97%, then N=250 patients would provide an estimate of the rate with a margin of error of 2%, with 95% confidence.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Locais de estudo
-
-
-
Essen, Alemanha, 45138
- Recrutamento
- Elisabeth Krankenhaus
-
Contato:
- Christopher Naber, MD
- Número de telefone: +492018970
- E-mail: c.naber@contilia.de
-
Contato:
- Elisabeth Blank, RN
- Número de telefone: +49 201 8973218
- E-mail: e.blank@contilia.de
-
Investigador principal:
- Christopher Naber, MD
-
-
-
-
-
Milan, Itália, 20162
- Recrutamento
- Ospedale Niguarda Ca' Granda
-
Investigador principal:
- Federico DeMarco, MD
-
Contato:
- Federico DeMarco, MD
- Número de telefone: +390264442585
- E-mail: federico.demarco@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Candidates for this study must meet all of the Indications criteria and none of the Contraindications.
Inclusion Criteria (Indications):
- Age > 70 years old
Severe aortic valve stenosis determined by echocardiogram and Doppler:
- mean gradient >40 mmHg or peak jet velocity >4.0 m/s
- aortic valve area ≤0.8 cm2 or aortic valve area index ≤0.5 cm2/m2
- Symptomatic aortic valve stenosis (angina, congestive heart failure, NYHA Functional Class ≥ II, or syncope).
- Patient is an extreme risk candidate for open surgical aortic valve repair such that the site Investigators (interventional cardiologist and cardiothoracic surgeon) agree that medical factors preclude operation, based on the conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement due to the patient's co-morbidities (such as, but not limited to, severe COPD, porcelain aorta, previous thorax irradiation) or logistic EuroSCORE ≥ 20.
Exclusion Criteria (Contraindications):
The Direct Flow Medical device is contraindicated for post implant balloon valvuloplasty.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
---|---|
aortic valve disease
aortic valve replacement
|
Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Freedom from all-cause mortality at 30 days
Prazo: 30 days
|
30 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Device Success (VARC defined)
Prazo: 30 days
|
|
30 days
|
Early Safety
Prazo: 30 days
|
|
30 days
|
Clinical efficacy
Prazo: 30 days through 5 years
|
|
30 days through 5 years
|
Clinical efficacy
Prazo: 30 days through 5 years
|
• NYHA Class III or IV
|
30 days through 5 years
|
Clinical efficacy
Prazo: 30 days through 5 years
|
• Prosthetic heart valve dysfunction (mean aortic valve gradient ≥20mm Hg, EOA ≤0.9-1.1cm2
[depending on body surface area] and/or DVI <0.35, AND/OR moderate or severe prosthetic valve regurgitation)
|
30 days through 5 years
|
Time-related Valve Safety
Prazo: 5 years
|
• Structural valve deterioration:
|
5 years
|
Time-related Valve Safety
Prazo: 5 years
|
|
5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Christopher Naber, MD, Elisabeth Krankenhaus Essen GmbH
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- RP 001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Aortic Valve Replacement
-
IsalaZorgvernieuwingConcluídoAterosclerose da Artéria Coronária
-
Shared Decision Making ResourcesEdwards LifesciencesConcluídoEstenose Aórtica SintomáticaEstados Unidos